Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry.
Atopic dermatitis
BIOREP
biological therapy
dupilumab
real-world
registries
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
pubmed:
17
2
2022
medline:
16
8
2022
entrez:
16
2
2022
Statut:
ppublish
Résumé
Dupilumab has been approved to treat moderate-to-severe atopic dermatitis; however, the data in a real-world setting are still limited. To analyze the effectiveness and safety of dupilumab. This was a real-life Czech multicenter retrospective study from patients treated with dupilumab for severe AD. A total of 360 patients were included. At 16 weeks, 66.6, 34.1, and 5.5% of patients achieved EASI75/90 and EASI100, respectively. Improvement continued with the time, and the proportion of patients with EASI75/90 and EASI100 increased to 89.5, 55.6, and 12.9% after one year of treatment and reached 95.8, 60.4, and 27.1% in the second year of therapy, respectively. A significant reduction was observed in the DLQI scores. The most common adverse events were infections in 5.8% of patients, followed by ocular complications in 2.5% of patients. Persistence rates were 98.2% at four months to 93.1% at month 24, and lack of effectiveness was the most common reason for discontinuation. This real-life study confirmed the effectiveness and safety of dupilumab in a real-life setting during the COVID-19 pandemic. Our study revealed a higher frequency of infections and a lower conjunctivitis frequency than other real-life studies and clinical trials.
Sections du résumé
BACKGROUND
UNASSIGNED
Dupilumab has been approved to treat moderate-to-severe atopic dermatitis; however, the data in a real-world setting are still limited.
OBJECTIVE
UNASSIGNED
To analyze the effectiveness and safety of dupilumab.
METHODS
UNASSIGNED
This was a real-life Czech multicenter retrospective study from patients treated with dupilumab for severe AD.
RESULTS
UNASSIGNED
A total of 360 patients were included. At 16 weeks, 66.6, 34.1, and 5.5% of patients achieved EASI75/90 and EASI100, respectively. Improvement continued with the time, and the proportion of patients with EASI75/90 and EASI100 increased to 89.5, 55.6, and 12.9% after one year of treatment and reached 95.8, 60.4, and 27.1% in the second year of therapy, respectively. A significant reduction was observed in the DLQI scores. The most common adverse events were infections in 5.8% of patients, followed by ocular complications in 2.5% of patients. Persistence rates were 98.2% at four months to 93.1% at month 24, and lack of effectiveness was the most common reason for discontinuation.
CONCLUSION
UNASSIGNED
This real-life study confirmed the effectiveness and safety of dupilumab in a real-life setting during the COVID-19 pandemic. Our study revealed a higher frequency of infections and a lower conjunctivitis frequency than other real-life studies and clinical trials.
Identifiants
pubmed: 35170381
doi: 10.1080/09546634.2022.2043545
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
dupilumab
420K487FSG
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM